Chardan gave MoonLake a Buy rating and a $57 per-share target, signaling a favorable view. This is an analyst opinion, not a report of improved company results, but the stated view favors MLTX.
A favorable outside opinion can draw attention to MoonLake's prospects. The report gives no new company results, so this view is not backed by a reported change in the business.
Follow MoonLake Immunotherapeutics (MLTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MLTX